# A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

Study · id `cardio:ct-nct07000357` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07000357](<https://clinicaltrials.gov/study/NCT07000357>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07000357

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 15100 participants.

## Technical summary

Registry record NCT07000357. Randomized; quadruple masking; primary purpose treatment. Start 2025-06-04 (actual); primary completion 2029-10-26 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 15100 participants (planned count; ClinicalTrials.gov record NCT07000357, source copy `cardio:ctgov-nct07000357-2026-08-24`, retrieved 2026-10-31)
- Started: 2025-06-04 (actual) (ClinicalTrials.gov record NCT07000357, source copy `cardio:ctgov-nct07000357-2026-08-24`, retrieved 2026-10-31)
- Primary completion: 2029-10-26 (anticipated) (ClinicalTrials.gov record NCT07000357, source copy `cardio:ctgov-nct07000357-2026-08-24`, retrieved 2026-10-31)
- Completion: 2029-10-26 (anticipated) (ClinicalTrials.gov record NCT07000357, source copy `cardio:ctgov-nct07000357-2026-08-24`, retrieved 2026-10-31)
- Countries: United States; Argentina; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czechia; Denmark; France; Germany; Greece; Hungary; India; Italy; Japan; Malaysia; Mexico; New Zealand; Peru; Philippines; Poland; Puerto Rico; Romania; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan; Thailand; Türkiye; Ukraine; United Kingdom; Vietnam (ClinicalTrials.gov record NCT07000357, source copy `cardio:ctgov-nct07000357-2026-08-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07000357-2026-08-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- Acronym: AZURE-Outcomes
- Condition: Cardiovascular Disease
- Intervention (Drug): AZD0780
- Intervention (Drug): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 7975b34a912c972437fbc74c49a01a8688abb8dc49e4d8d3d29f8d2bc5e2c3de
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
